NASDAQ:RGLS Regulus Therapeutics (RGLS) Stock Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free RGLS Stock Alerts $2.25 -0.02 (-0.88%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$2.20▼$2.3650-Day Range$1.38▼$2.8852-Week Range$1.08▼$3.79Volume612,282 shsAverage Volume2.21 million shsMarket Capitalization$147.29 millionP/E RatioN/ADividend YieldN/APrice Target$7.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Regulus Therapeutics alerts: Email Address Regulus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside222.2% Upside$7.25 Price TargetShort InterestBearish10.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.52) to ($0.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.41 out of 5 starsMedical Sector471st out of 915 stocksPharmaceutical Preparations Industry216th out of 426 stocks 4.4 Analyst's Opinion Consensus RatingRegulus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRegulus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regulus Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.92% of the float of Regulus Therapeutics has been sold short.Short Interest Ratio / Days to CoverRegulus Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regulus Therapeutics has recently increased by 15.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegulus Therapeutics does not currently pay a dividend.Dividend GrowthRegulus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RGLS. Previous Next 1.9 News and Social Media Coverage News SentimentRegulus Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Regulus Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 17 people have searched for RGLS on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Regulus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regulus Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.35% of the stock of Regulus Therapeutics is held by insiders.Percentage Held by Institutions92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regulus Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.52) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regulus Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regulus Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegulus Therapeutics has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Regulus Therapeutics Stock (NASDAQ:RGLS)Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More RGLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGLS Stock News HeadlinesMay 9, 2024 | msn.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024May 9, 2024 | prnewswire.comRegulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 10, 2024 | Stansberry Research (Ad)Things Are Not Normal in America – Here’s What to DoGet Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.May 8, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Rating Reiterated by HC WainwrightMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus’s Innovative ADPKD Therapy RGLS8429May 7, 2024 | americanbankingnews.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of "Moderate Buy" by AnalystsMay 6, 2024 | prnewswire.comRegulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)May 2, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Shares Pass Above Two Hundred Day Moving Average of $1.66May 10, 2024 | Stansberry Research (Ad)Things Are Not Normal in America – Here’s What to DoGet Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.April 30, 2024 | prnewswire.comRegulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesApril 10, 2024 | seekingalpha.comRegulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKDMarch 28, 2024 | markets.businessinsider.comBuy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment NeedsMarch 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development MilestonesMarch 23, 2024 | finance.yahoo.comRegulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical AdvancementsMarch 22, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesMarch 21, 2024 | investorplace.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023March 21, 2024 | finance.yahoo.comRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment DataMarch 15, 2024 | finance.yahoo.comRGLS Mar 2024 7.500 putMarch 14, 2024 | finance.yahoo.comBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & MoreMarch 13, 2024 | markets.businessinsider.comRegulus’s Stock RGLS: Hold Rating Amidst Promising Yet Preliminary ADPKD Study Results and Financial PositionMarch 12, 2024 | marketwatch.comRegulus Therapeutics Shares Soar on Funding, Study DataMarch 12, 2024 | markets.businessinsider.comRegulus Surges 60% On Positive Outcome From Phase1b MAD Trial, Private Placement Of $100 MlnMarch 12, 2024 | msn.comWhy Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?March 12, 2024 | markets.businessinsider.comRegulus Announces $100 Mln Private Placement, Positive Data From Phase 1b MAD Trial Of RGLS8429March 12, 2024 | msn.comConsumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-BellMarch 12, 2024 | prnewswire.comRegulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquitySee More Headlines Receive RGLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RGLS CUSIP75915K10 CIK1505512 Webwww.regulusrx.com Phone(858) 202-6300FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$7.25 High Stock Price Target$11.00 Low Stock Price Target$3.00 Potential Upside/Downside+222.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-109.21% Return on Assets-80.55% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book2.14Miscellaneous Outstanding Shares65,460,000Free Float62,617,000Market Cap$147.29 million OptionableOptionable Beta1.59 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Joseph P. Hagan M.B.A. (Age 55)CEO & Director Comp: $920.73kMs. Crispina Calsada CPA (Age 54)Chief Financial Officer Comp: $500.87kMr. Christopher Ray Aker J.D. (Age 63)Senior VP, General Counsel & Corporate Secretary Comp: $524.79kDr. Preston S. Klassen M.D. (Age 55)M.H.S., President, Head of Research & Development and Director Mr. Daniel J. Penksa (Age 38)VP of Finance & Controller Dr. Claire Susan Padgett M.S.M.T., Ph.D., Senior Vice President of Clinical OperationsDr. Rekha Garg M.D.M.S., Senior Vice President of Clinical Development & RegulatoryMr. Edmund Lee Ph.D.Vice President of Translational MedicineMore ExecutivesKey CompetitorsAlimera SciencesNASDAQ:ALIMRigel PharmaceuticalsNASDAQ:RIGLMerrimack PharmaceuticalsNASDAQ:MACKEmergent BioSolutionsNYSE:EBSBolt BiotherapeuticsNASDAQ:BOLTView All CompetitorsInsiders & InstitutionsCVI Holdings LLCBought 1,406,250 shares on 5/7/2024Ownership: 2.148%Vivo Capital LLCBought 5,000,000 shares on 4/22/2024Ownership: 7.638%Joseph P HaganSold 14,580 sharesTotal: $17,350.20 ($1.19/share)Crispina CalsadaSold 5,468 sharesTotal: $6,506.92 ($1.19/share)View All Insider TransactionsView All Institutional Transactions RGLS Stock Analysis - Frequently Asked Questions Should I buy or sell Regulus Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGLS shares. View RGLS analyst ratings or view top-rated stocks. What is Regulus Therapeutics' stock price target for 2024? 5 analysts have issued 1-year target prices for Regulus Therapeutics' stock. Their RGLS share price targets range from $3.00 to $11.00. On average, they predict the company's share price to reach $7.25 in the next year. This suggests a possible upside of 222.2% from the stock's current price. View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts. How have RGLS shares performed in 2024? Regulus Therapeutics' stock was trading at $1.28 at the start of the year. Since then, RGLS stock has increased by 75.8% and is now trading at $2.25. View the best growth stocks for 2024 here. How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc. (NASDAQ:RGLS) announced its earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40). When did Regulus Therapeutics' stock split? Regulus Therapeutics's stock reverse split on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO? 2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN). Who are Regulus Therapeutics' major shareholders? Regulus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vivo Capital LLC (7.64%) and CVI Holdings LLC (2.15%). Insiders that own company stock include Christopher Ray Aker, Crispina Calsada, Denis Drygin and Joseph P Hagan. View institutional ownership trends. How do I buy shares of Regulus Therapeutics? Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RGLS) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
